

Oral symptoms potentially associated with mild-to-moderate COVID-19 in tobacco users

Hanaa E. Alkharobi¹, Manar M. Alzahrani², Shatha Bamashmous³, Abdullah Alghamdi⁴

ABSTRACT

INTRODUCTION Coronavirus disease (COVID-19) is a worldwide infection characterized by various symptoms. Few studies have examined its oral manifestations. However, there is insufficient information on the oral manifestations of patients with COVID-19 who use tobacco products. Therefore, this cross-sectional study investigated oral symptoms of tobacco-using patients with mild-to-moderate COVID-19.

METHODS This study used a convenience sample of non-hospitalized patients (aged ≥ 18 years) with mild-to-moderate COVID-19 diagnosed by polymerized chain reaction (PCR). This study excluded pregnant or lactating women or patients with serious COVID-19 complications, including those who required hospitalization or were on specific medications (antiviral, corticosteroid, antimicrobial, or immunosuppressive). Oral examinations were performed, including labial, buccal, and gingival mucosa, tongue, floor of the mouth, and palate, for any newly developed lesions associated with the onset of COVID-19. The salivary flow was determined using the passive drool collection technique.

RESULTS Lip dryness, gingivitis, tongue lesions, and taste loss were the most commonly reported oral symptoms in patients with mild-to-moderate COVID-19. The most common general symptoms were tiredness and headache (63.9%), followed by dry cough, myalgia, sore throat, and fever. This study found 139 occurrences of oral symptoms, of which 52 were dry lips (27 tobacco non-users, and 25 tobacco users), and 11 were gingivitis (five non-users, and six tobacco users), and 12 tongue changes (eight non-users, and four tobacco users). Ageusia, or loss of taste sensation, was most commonly reported with or without other oral COVID-19 symptoms (55 occurrences: 36 non-users and 19 tobacco users). No significant differences were found in oral symptoms between tobacco non-users and tobacco users.

CONCLUSIONS There is a need to expand the routine examination protocol for patients during future respiratory pandemics, as monitoring oral health allows dentists to improve the management of oral sequelae during a pandemic.

AFFILIATION

1 Department of Oral Biology, College of Dentistry, King Abdul-Aziz University, Jeddah, Saudi Arabia

2 Department of Oral and Maxillofacial Prosthodontics, Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia

3 Department of Periodontology, Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia

4 Ministry of Health, Jeddah, Saudi Arabia

CORRESPONDENCE TO

Hanaa E. Alkharobi.

Department of Oral Biology, College of Dentistry, King Abdul-Aziz University, 21589 Jeddah, Saudi Arabia.

E-mail: halkharobi@kau.edu.sa

ORCID iD: <https://orcid.org/0000-0002-8912-9016>

KEYWORDS

COVID-19, oral manifestations, tobacco products, ageusia

Received: 27 April 2023

Revised: 6 January 2024

Accepted: 26 March 2024

INTRODUCTION

Coronavirus disease (COVID-19) is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 imparts respiratory and extra-respiratory clinical signs and symptoms¹. A surface protein of SARS-CoV-2 has a high binding affinity for angiotensin-converting enzyme-2 (ACE2) receptors. ACE2 is expressed on keratinized epithelial cell surfaces of

the oral cavity, including the dorsum of the tongue, hard palate, and salivary glands. Viral invasion of oral tissues through this receptor causes several changes, including inflammatory reactions in the tongue mucosal membrane and salivary gland tissues². The high expression levels could explain potentially observed oral symptoms in patients with COVID-19.

Several oral symptoms may be linked to the COVID-19, including tongue depapillation, candida-associated lesions, xerostomia, aphthous-like lesions, recurrent herpes virus infection, ulcers, blisters, gingivitis, gingival bleeding, necrotizing gingivitis, white/erythematous plaques, and salivary gland alterations. Loss of smell and taste with altered taste-bud sensitivity is also associated with COVID-19 oral lesions³.

The etiology of oral symptoms in patients with COVID-19 remains unclear; however, many possible molecular and cellular mechanisms have been suggested. Recent studies have indicated that: 1) the interaction between the virus and ACE2 receptors potentially interrupts cell integrity, inducing oral lesions; 2) the medications used to treat COVID-19 may trigger oral lesions, including herpes simplex virus, candida infection, ulceration, and gingivitis; and 3) oral lesions may develop due to the effect of SARS-CoV-2 on the immune system, increasing the risk of co-infection with opportunistic bacteria, fungi, and viruses. Oral lesions often resolve when COVID-19 symptoms subside⁴, confirming an association between COVID-19 and clinical oral symptoms.

Tobacco use is also a critical risk factor for the development of oral mucosal lesions ranging from benign mucosal changes to precancerous and cancerous lesions. Tobacco use is associated with periodontitis, halitosis, caries, and alveolar osteitis, resulting in a significant health burden. Smoking cigarettes often involves hand-to-mouth contact, and smokeless tobacco, including chewing tobacco, helps spread microorganisms when the user spits out saliva produced during the chewing process⁵. Moreover, tobacco use reduces the effectiveness of the immune system, making tobacco users more susceptible to diseases with poor prognoses⁶.

However, the prevalence of oral symptoms associated with COVID-19 onset among tobacco users remains unclear. This cross-sectional study

investigated the oral symptoms in patients with mild-to-moderate COVID-19 to determine whether tobacco products intensify oral symptoms at disease onset.

METHODS

Study design and selection of patients

This cross-sectional study was conducted between January and March 2020. We selected a convenience sample from COVID-19 patients who were recruited to the Tetamman Primary Health Care Center based on their polymerase chain reaction (PCR)-positive results, which detected the presence of viral genetic material in nasopharyngeal or throat swabs. Patients were referred to the center to receive their medications. Our inclusion criteria were adult patients (aged ≥ 18 years), confirmed COVID-19 positive results, mild-to-moderate symptoms (fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell, and lack of shortness of breath, dyspnea, or abnormal chest imaging), no hospitalization, and enrollment within seven days of diagnosis. Patients were excluded if they were pregnant or lactating, had serious COVID-19 complications (e.g. severe pneumonia, severe dyspnea, increased respiratory rate >30 breaths/min, decreased oxygen saturation $<93\%$), required hospitalization, or were on established antiviral, corticosteroid, antimicrobial, or immunosuppressive medications. When eligibility was determined, informed consent was obtained, the patient was interviewed, and an oral examination was conducted. Ethical approval was obtained from the Ethics Committee of the Directorate of Health Affairs, Ministry of Health, Jeddah, Saudi Arabia (protocol number: H-02-J-002; 1384). The study was conducted in accordance with the relevant guidelines and regulations of the Ministry of Health and the principles of the Declaration of Helsinki.

The power analysis in this study was computed using an alpha of 0.05 and a statistical power of 0.8 to estimate an effect size of 0.20 using the power program (G*Power software, version 3.1.9.7; Christian-Albrechts-Universität Kiel, Kiel, Germany).

Data collection

Demographic data, medical history, and general COVID-19 symptoms were collected. We asked the patients about their perceptions of gustatory and

olfactory dysfunction. Trained qualified dentists conducted meticulous examinations to assess the presence of oral lesions and conditions. The examination included inspection of the labial, buccal, and gingival mucosa, tongue, floor of the mouth, and palate for any newly developed inflammation, erythema, petechiae, ulcers, and macules. Tobacco-associated lesions (i.e. tobacco-induced melanosis) were excluded. The clinical diagnosis of oral mucosa was based on World Health Organization (WHO) criteria. The clinical diagnosis of mucosal lesions in the chewers was based on the criteria described by Zain et al.⁷ Data collection and clinical examination were performed by three examiners, and any abnormalities were reported after consultation and agreement among them.

Oral examinations were performed in a dental clinic under direct illumination built into the dental unit using a sterilized disposable mouth mirror and a probe. Strict precautions were taken, including wearing complete personal protective equipment, including disposable isolation gowns, sterile gloves, N95 masks, goggles, and face shields.

The salivary flow of all participants was determined using 50 mL calibrated Falcon sterile test tubes. Unstimulated whole-saliva samples were collected using the passive drool collection technique. Participants were asked not to talk, eat, drink, smoke, or chew anything for 30 min before giving the saliva samples. Participants were asked to swallow their saliva before the collection procedure began. Subsequently, they were asked to collect their saliva by drooling into a 50 mL sterile tube. The unstimulated salivary flow rate was considered normal when it was 0.25–0.4 mL/min. Any reported flow <0.25 mL/min was considered low and a sign of oral dryness and salivary hypofunction.

Statistical analysis

Data that were collected were edited and screened before entering into version 22 of the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA). All statistical tests were two-tailed, and a $p < 0.05$ was considered statistically significant. Descriptive statistics were used to compute the frequencies and percentages for all categorical variables, whereas means were used to describe the

scale variables. Chi-squared and Fisher's exact tests were used to assess the statistical significance of the associations between categorical variables. Backward logistic regression was used for multivariate analysis adjusting for age, sex, marital status, nationality, tobacco use, and chronic diseases were included in Step 1 of the analysis. Adjusted odds ratios (AOR) and their 95% confidence intervals (CIs) were calculated.

RESULTS

This cross-sectional study included 122 participants (90 male and 32 female) diagnosed with COVID-19 with mild-to-moderate symptoms. The characteristics of the participants included in this study are presented in Table 1. Mean (SD) age was 35.4 (10.7) years for

Table 1. Sample characteristics of non-hospitalized patients, aged ≥ 18 years, recruited to the Tetamman Primary Health Care Center with mild-to-moderate COVID-19 diagnosed by polymerized chain reaction (PCR), between January and March 2020 (N=122)

Characteristics	Overall (N=122) n (%)	Patients showing oral manifestations associated with COVID-19 (N=41) n (%)
Age (years)		
18–29	39 (32)	11 (26.8)
30–39	44 (36.1)	14 (34.1)
40–49	25 (20.5)	11 (26.8)
≥ 50	14 (11.5)	5 (12.2)
Sex		
Male	90 (73.8)	30 (73.2)
Female	32 (26.2)	11 (26.8)
Marital status		
Single	40 (32.8)	12 (29.3)
Married	80 (65.6)	28 (68.3)
Divorced	2 (1.6)	1 (2.4)
Nationality		
Saudi	37 (30.3)	12 (29.3)
Non-Saudi	85 (69.7)	29 (70.7)
Chronic disease		
Diabetes	6 (4.9)	2 (4.9)
Hypertension	5 (4.1)	3 (7.3)
High cholesterol	2 (1.6)	1 (2.4)
Asthma	1 (0.8)	0 (0)

Table 2. General symptoms in non-hospitalized patients, aged ≥ 18 years, recruited to the Tetamman Primary Health Care Center with mild-to-moderate COVID-19 diagnosed by polymerized chain reaction (PCR), with and without tobacco habits, between January and March 2020 (N=122)

General symptoms	Overall (N=122) n (%)	No habits (N=76) n (%)	Tobacco users (N=46) n (%)	Pearson χ^2	p
Fever				0.11	0.740
Yes	56 (45.9)	34 (44.7)	22 (47.8)		
No	66 (54.1)	42 (55.3)	24 (52.2)		
Chills				0.34	0.561
Yes	49 (40.2)	29 (38.2)	20 (43.5)		
No	73 (59.8)	47 (61.8)	26 (56.5)		
Runny nose				0.21	0.651
Yes	32 (26.2)	21 (27.6)	11 (23.9)		
No	90 (73.8)	55 (72.4)	35 (76.1)		
Tiredness				0.05	0.818
Yes	78 (63.9)	48 (63.2)	30 (65.2)		
No	44 (36.1)	28 (36.8)	16 (34.8)		
Sore throat				0.37	0.544
Yes	62 (50.8)	37 (48.7)	25 (54.3)		
No	60 (49.2)	39 (51.3)	21 (45.7)		
Dry cough				0.18	0.674
Yes	74 (60.7)	45 (59.2)	29 (63.0)		
No	48 (39.3)	31 (40.8)	17 (37.0)		
Shortness of breath				0.30	0.583
Yes	44 (36.1)	26 (34.2)	18 (39.1)		
No	78 (63.9)	50 (65.8)	28 (60.9)		
Chest pain				0.17	0.682
Yes	29 (23.8)	19 (25.0)	10 (21.7)		
No	93 (76.2)	57 (75.0)	36 (78.3)		
Headache				1.02	0.314
Yes	78 (63.9)	46 (60.5)	32 (69.6)		
No	44 (36.1)	30 (39.5)	14 (30.4)		
Myalgia				0.15	0.702
Yes	69 (56.6)	44 (57.9)	25 (54.3)		
No	53 (43.4)	32 (42.1)	21 (45.7)		
Diarrhea				0.67	0.413
Yes	27 (22.1)	15 (19.7)	12 (26.1)		
No	95 (77.9)	61 (80.3)	34 (73.9)		
Skin rash				1.10*	0.556
Yes	3 (2.5)	1 (1.3)	4 (8.7)		
No	119 (97.5)	75 (98.7)	2 (4.3)		
Vomiting				2.25*	0.197
Yes	6 (4.9)	2 (2.6)	4 (8.7)		
No	116 (95.1)	74 (97.4)	42 (91.3)		

Continued

Table 2. Continued

General symptoms	Overall (N=122) n (%)	No habits (N=76) n (%)	Tobacco users (N=46) n (%)	Pearson χ^2	p
Nausea				0.30*	0.765
Yes	13 (10.7)	9 (11.8)	4 (8.7)		
No	109 (89.3)	67 (88.2)	42 (91.3)		
Red painful eye				0.55*	0.474
Yes	8 (6.6)	4 (5.3)	4 (8.7)		
No	114 (93.4)	72 (94.7)	42 (91.3)		
Loss of smell				0.14	0.709
Yes	61 (50.0)	39 (51.3)	22 (47.8)		
No	61 (50.0)	37 (48.7)	24 (52.2)		

*Fisher's exact test. Statistical significance at $p < 0.05$.

Table 3: Oral mucosal lesions in non-hospitalized patients, aged ≥ 18 years, recruited to the Tetamman Primary Health Care Center with mild-to-moderate COVID-19 diagnosed by polymerized chain reaction (PCR), with and without tobacco habits, between January and March 2020 (N=122)

Oral manifestations	Occurrence in tobacco users n (%)	Occurrence in tobacco non-users n (%)	p
Dry lips	25 (54.3)	27 (35.5)	0.562
Dry buccal and labial mucosa	1 (2.2)	1 (1.3)	0.718
Small blisters in buccal and labial mucosa	0 (0.0)	1 (1.3)	0.435
Brown pigmentation (smoker melanosis)	1 (2.2)	0 (0.0)	0.197
Smokeless tobacco lesion	2 (4.3)	0 (0.0)	0.067
Gingival inflammation	6 (8.7)	5 (7.9)	0.876
White and erythematous gingiva	2 (4.3)	0 (0.0)	0.067
Dry tongue	3 (6.5)	3 (3.9)	0.524
Fissured tongue	0 (0.0)	1 (1.3)	0.435
Geographic tongue	0 (0.0)	1 (1.3)	0.435
Reddish macule in the tongue	0 (0.0)	1 (1.3)	0.435
Mass on the side of the tongue	0 (0.0)	1 (1.3)	0.435
Tongue ulcers	1 (2.2)	1 (1.3)	0.718
Dry mucosa on the floor of the mouth	0 (0.0)	1 (1.3)	0.435
Loss of taste	19 (41.3)	36 (47.4)	0.514

all the participants, 32.0 (10.0) years for females, and 36.6 (10.7) years for males. Most participants were aged 30–39 years, and the smallest group had participants aged >50 years. Most participants were male, married, and non-Saudi citizens. Diabetes was the most common chronic disease among study participants, followed by hypertension, high cholesterol levels, and asthma (Table 1).

Approximately 38% of the participants were tobacco users, and the majority of them were male.

The overall results among tobacco non-users and tobacco users showed that tiredness and headache were the most common general symptoms reported in this study (63.9%), followed by dry cough, myalgia, sore throat, and fever. Approximately 50% of participants reported a loss of smell as a COVID-19

Table 4. Variables associated with oral manifestations in multiple logistic regression in non-hospitalized patients, aged ≥ 18 years, recruited to the Tetamman Primary Health Care Center with mild-to-moderate COVID-19 diagnosed by polymerized chain reaction (PCR), with and without tobacco habits, between January and March 2020 (N=122)

Variable	B	Wald	p	AOR (95% CI)
Tobacco use status				
User	0.682	2.4	0.117	1.97 (0.84–4.64)
Non-user [®]				1
Gender				
Female	0.921	3.2	0.034	2.73 (1.08–6.90)
Male [®]				1

AOR: adjusted odds ratio. Backward logistic regression was used for multivariate analysis. Age, sex, marital status, nationality, tobacco use, and chronic diseases were included in Step 1 of the analysis. [®] Reference categories.

symptom. General symptoms were higher in non-users than in tobacco users, except for skin rashes and vomiting, which were higher in tobacco users (95.7% and 8.7%, respectively). However, we identified a non-significant difference in general symptoms between non-users and tobacco users (Table 2).

The observed occurrences and sites of oral manifestations and lesions in mild-to-moderate COVID-19 patients are shown in Table 3. This study reported 139 occurrences of oral symptoms, of which 52 were dry lips (27 non-users and 25 tobacco users), and 11 were gingivitis (five non-users and six tobacco users). We also found 12 changes in the tongue (eight non-users and four tobacco users), including dry tongue, fissured tongue, geographic tongue, reddish macules in the tongue, mass on the tongue side, and tongue ulcers. Some patients experienced multiple symptoms. Ageusia, or loss of the sense of taste, was most commonly reported with or without other oral COVID-19 symptoms (55 occurrences: 36 non-users and 19 tobacco users), as shown in Table 3. Statistical analysis of reported oral symptoms showed no significant differences between non-users and tobacco users with regard to COVID-19 oral symptoms.

We found that 51% of non-users had normal salivary flow rates compared with 67% of tobacco users. However, 49% of non-users showed a low flow rate during saliva collection compared to 33% of tobacco users; however, the difference was not significant.

Backward logistic regression was used for multivariate analysis. Age, sex, marital status, nationality, tobacco

use, and chronic diseases were included in the analysis. The analysis yielded a final significant model that included two variables. Women were significantly more likely to have oral manifestations compared to men (AOR=2.73; 95% CI: 1.08–6.90). There was no significant difference in oral manifestation between tobacco users and non-users (AOR=1.97; 95% CI: 0.84–4.64) (Table 4).

DISCUSSION

The lack of sufficient information regarding the prevalence of oral symptoms in mild-to-moderate COVID-19 disease among tobacco users prompted a need to identify the oral symptoms in this patient group. Of the participants, 38% used different forms of tobacco, including conventional cigarettes, e-cigarettes, hookahs, and smokeless tobacco (e.g. chewing tobacco).

We included tobacco users in this study because previous studies have shown that tobacco use can make individuals more susceptible to COVID-19⁸. This may be because smoking habits facilitate cross-infection through contaminated fingers, cigarettes, pipes, and mouth, thereby increasing the risk of SARS-CoV-2 transmission. Hookah smoking involves the sharing of different mouthpieces, which facilitates SARS-CoV-2 transmission. Finally, COVID-19 can be transmitted via a viral load in excess saliva expectorated while chewing tobacco⁸.

In the present study, patients reported different general symptoms of COVID-19, including fatigue, headache, dry cough, myalgia, sore throat, fever, and

loss of smell. This is consistent with several clinical studies that observed similar symptoms in mild and moderate cases of COVID-19⁹. In addition, 47% of tobacco users were male, and 13% were female. This is similar to the results of other studies in which predominant tobacco users were males¹⁰. However, Lima et al.¹¹ showed a female predominance in tobacco use. The majority of the participants in the current study who used tobacco were aged 30–39 years. In contrast, other studies reported that the majority of the patients in the conventional smoking group were aged 50–65 years, whereas those aged 18–33 years dominated the smokeless tobacco group¹².

The study findings suggest that the lips, gingiva, and tongue are the locations of oral manifestations of COVID-19. Moreover, single or multiple oral symptoms were observed in patients with COVID-19. These findings are consistent with previous reports that the tongue, gingiva, and lips are the main sites of oral manifestations of COVID-19^{13–15}. The concurrent appearance of two or three oral symptoms can be attributed to ACE2 receptor expression in various oral tissues. High expression in the oral cavity is significantly associated with the oral manifestations of COVID-19, and the interaction between SARS-CoV-2 and this receptor is essential for inducing changes in the oral epithelium. Studies have reported that oral lesions are observed in 2–20% of patients with COVID-19^{16,17}. Other studies have shown that oral lesions associated with the onset of COVID-19 resolve automatically when the infection subsides, indicating an association between the disease and reported oral symptoms³.

Oral symptoms reported in this study included dryness, inflammation, and ulcers. A recent study reported several ulcers during oral examinations in patients with COVID-19, which were related to the stress associated with the infection¹⁸. Ulcers are indirectly linked to COVID-19 by potentially triggering nervous habit consequences, increasing blood pressure, and poor diet^{19,20}. The present results are also consistent with those of a recently published review, wherein oral symptoms, such as taste alterations and mucosal ulcerations, were identified during oral examination of patients with COVID-19²¹. Additionally, gingivitis was observed among the oral symptoms reported in this study.

Regarding the periodontium, COVID-19 has been shown to affect the patient's immune system, which is associated with: 1) an increase in the level of infectious agents that correlates with the development of periodontal conditions²², 2) high expression of cytokines, or 'cytokine storm', which may lead to tissue destruction^{23,24}; and 3) increased fibrinogen degradation product levels as the coagulation cascade is activated during inflammation²⁵.

Olfactory and gustatory dysfunctions were the most frequently reported symptoms in this study, independent of other oral manifestations of COVID-19. Song et al.¹⁶ reported a more frequent occurrence of gustatory dysfunction (21%) than olfactory dysfunction (11%) in patients with COVID-19, which is consistent with the results of the present study. Furthermore, the results here are consistent with previous studies reporting that gustatory dysfunction manifests in approximately 63%, 66%, 60.7%, and 45%^{2, 26, 27}, of patients with COVID-19. The mechanisms underlying changes in smell and taste sensations caused by COVID-19 remain unclear. However, smell and taste dysfunctions may be attributed to the interaction of SARS-CoV-2 with the ACE2 receptor, which is broadly expressed by respiratory epithelial cells and oral mucosal tissues, predominantly in the tongue²⁸.

Other hypotheses have suggested that the relationship between COVID-19 and loss of taste might be related to rhinitis, which initiates an inflammatory response that subsequently impairs normal taste bud function²⁹. However, in many cases, loss of taste is not associated with nasal mucosal inflammation. The loss of taste in patients is linked to: 1) the inability to recognize food odor due to olfactory dysfunction, and 2) the failure to dissolve food molecules to enter the taste receptors due to saliva deficiency³⁰. Conversely, olfactory dysfunction is caused by the mechanical obstruction of odorant transmission in the olfactory cleft due to mucosal inflammation, leading to olfactory epithelium degeneration and loss of smell³¹.

More than half of the participants retained a normal salivary flow rate during the SARS-CoV-2 infection period, regardless of tobacco use. However, approximately 49% of tobacco non-users and 33% of tobacco users exhibit low salivary flow rates. These results are consistent with those of previously

reported cases of xerostomia⁹. Changes in salivary flow and composition in patients with COVID-19 may be explained by the damage to the epithelial cells of the salivary glands caused by SARS-CoV-2³². This result is similar to those of respiratory tract infections in which xerostomia has been reported³³. As ACE2-positive cells are expressed in the salivary gland duct epithelial cells, it is hypothesized that viral infection activates pathological inflammatory lesions in the salivary glands, leading to lysis and epithelial cell damage and causing alterations in salivary flow²⁸. Moreover, xerostomia experienced by COVID-19 patients may be caused by anxiety due to stressful conditions.

Clinical evidence has demonstrated that the oral cavity is the main site of SARS-CoV-2 entry. Therefore, the symptoms presented during COVID-19 onset are oral manifestations of COVID-19³⁴, although this remains unclear. It has been hypothesized that the reported oral symptoms may be caused by COVID-19 disease, which promotes favorable conditions for the development of opportunistic viral or bacterial infections in the oral cavity. Therefore, it is crucial to maintain reasonable oral hygiene to control COVID-19 oral complications because of the established link between bacterial loads in the oral cavity and COVID-19 symptoms³⁵.

Limitations

All results reported in this article should be interpreted with caution. Taste loss could be subjective, as it was self-reported, and may not be diagnostic of this symptom. A more accurate classification of taste disorders may improve the measurement of this trait. The difficulty in recruiting patients with COVID-19 more than once due to their health conditions resulted in oral examinations being performed only once. Conducting oral examinations regularly every three days from the first day of onset to day 14 would provide a clearer picture of changes in oral health. Moreover, this study was conducted in one city in the Kingdom of Saudi Arabia, which may limit its generalizability. Another limitation is its cross-sectional design, which makes it impossible to prove causality between the variables. In addition, there is a lack of power in the comparison of tobacco users and non-users and the absence of comparisons with non-

COVID-19 patients. Moreover, in such a small sample size, it would be preferable not to compare women and men unless a suitable sample size is established for both sexes.

CONCLUSIONS

The COVID-19 pandemic caused by SARS-CoV-2 had a variety of consequences affecting oral health. Among the oral symptoms associated with mild-to-moderate COVID-19, dry lips, gingivitis, tongue lesions, and loss of taste were the most prevalent. However, there were no significant differences in oral symptoms between tobacco users and non-users with mild-to-moderate COVID-19. In dental clinics, meticulous oral examinations should be performed during any pandemic as part of the routine examinations to detect associated oral symptoms.

REFERENCES

1. Riad A, Klugar M, Krsek M. COVID-19-related oral manifestations: early disease features?. *Oral Dis.* 2022;28 Suppl 1(Suppl 1):940-942. doi:[10.1111/odi.13516](https://doi.org/10.1111/odi.13516)
2. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. *Clin Infect Dis.* 2020;71(15):889-890. doi:[10.1093/cid/ciaa330](https://doi.org/10.1093/cid/ciaa330)
3. Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. *Cell Prolif.* 2020;53(12):e12923. doi:[10.1111/cpr.12923](https://doi.org/10.1111/cpr.12923)
4. Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. *BMC Public Health.* 2018;18(1):574. doi:[10.1186/s12889-018-5484-8](https://doi.org/10.1186/s12889-018-5484-8)
5. Abubakr N, Salem ZA, Kamel AHM. Oral manifestations in mild-to-moderate cases of COVID-19 viral infection in the adult population. *Dent Med Probl.* 2021;58(1):7-15. doi:[10.17219/dmp/130814](https://doi.org/10.17219/dmp/130814)
6. Al-Mutawa SA, Shyama M, Al-Duwairi Y, Soparkar P. Oral hygiene status of Kuwaiti schoolchildren. *East Mediterr Health J.* 2011;17(5):387-391. doi:[10.26719/2011.17.5.387](https://doi.org/10.26719/2011.17.5.387)
7. Zain RB, Ikeda N, Gupta PC, et al. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25-27, 1996. *J Oral Pathol Med.* 1999;28(1):1-4. doi:[10.1111/j.1600-0714.1999.tb01985.x](https://doi.org/10.1111/j.1600-0714.1999.tb01985.x)
8. Paleiron N, Mayet A, Marbac V, et al. Impact of tobacco smoking on the risk of COVID-19: a large scale retrospective cohort study. *Nicotine Tob Res.* 2021;23(8):1398-1404. doi:[10.1093/ntr/ntab004](https://doi.org/10.1093/ntr/ntab004)
9. Vaira LA, Salzano G, Petrocelli M, Deiana G, Salzano FA, De Riu G. Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19

- patients in home quarantine. *Head Neck*. 2020;42(7):1570-1576. doi:[10.1002/hed.26228](https://doi.org/10.1002/hed.26228)
10. Chockalingam K, Vedhachalam C, Rangasamy S, et al. Prevalence of tobacco use in urban, semi urban and rural areas in and around Chennai City, India. *PLoS One*. 2013;8(10):e76005. doi:[10.1371/journal.pone.0076005](https://doi.org/10.1371/journal.pone.0076005)
 11. Lima JS, Pinto Ddos S Jr, Sousa SO, Corrêa L. Oral leukoplakia manifests differently in smokers and non-smokers. *Braz Oral Res*. 2012;26(6):543-549. doi:[10.1590/s1806-83242012005000024](https://doi.org/10.1590/s1806-83242012005000024)
 12. Iruasa KF, Vence B, Donovan T. Potential oral health effects of e-cigarettes and vaping: a review and case reports. *J Esthet Restor Dent*. 2020;32(3):260-264. doi:[10.1111/jerd.12583](https://doi.org/10.1111/jerd.12583)
 13. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2001;92(6):641-649. doi:[10.1067/moe.2001.118478](https://doi.org/10.1067/moe.2001.118478)
 14. Aragoneses J, Suárez A, Algar J, Rodríguez C, López-Valverde N, Aragoneses JM. Oral manifestations of COVID-19: updated systematic review with meta-analysis. *Front Med (Lausanne)*. 2021;8:726753. doi:[10.3389/fmed.2021.726753](https://doi.org/10.3389/fmed.2021.726753)
 15. Baghizadeh Fini M. Oral saliva and COVID-19. *Oral Oncol*. 2020;108:104821. doi:[10.1016/j.oraloncology.2020.104821](https://doi.org/10.1016/j.oraloncology.2020.104821)
 16. Song J, Deng YK, Wang H, et al. Self-reported taste and smell disorders in patients with COVID-19: distinct features in China. *Curr Med Sci*. 2021;41(1):14-23. doi:[10.1007/s11596-021-2312-7](https://doi.org/10.1007/s11596-021-2312-7)
 17. Kramer IR, Pindborg JJ, Bezroukov V, Infirri JS. Guide to epidemiology and diagnosis of oral mucosal diseases and conditions. World Health Organization. *Community Dent Oral Epidemiol*. 1980;8(1):1-26. doi:[10.1111/j.1600-0528.1980.tb01249.x](https://doi.org/10.1111/j.1600-0528.1980.tb01249.x)
 18. Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, et al. Oral mucosal lesions in a COVID-19 patient: new signs or secondary manifestations?. *Int J Infect Dis*. 2020;97:326-328. doi:[10.1016/j.ijid.2020.06.012](https://doi.org/10.1016/j.ijid.2020.06.012)
 19. de Sousa FACG, Paradella TC. Considerations on oral manifestations of COVID-19. *J Med Virol*. 2021;93(2):667-668. doi:[10.1002/jmv.26451](https://doi.org/10.1002/jmv.26451)
 20. Costa KVT, Carnaúba ATL, Rocha KW, Andrade KCL, Ferreira SMS, Menezes PL. Olfactory and taste disorders in COVID-19: a systematic review. *Braz J Otorhinolaryngol*. 2020;86(6):781-792. doi:[10.1016/j.bjorl.2020.05.008](https://doi.org/10.1016/j.bjorl.2020.05.008)
 21. Surboyo MD, Ernawati DS, Budi HS. Oral mucosal lesions and oral symptoms of the SARS-CoV-2 infection. *Minerva Dent Oral Sci*. 2021;70(4):161-168. doi:[10.23736/S2724-6329.21.04493-9](https://doi.org/10.23736/S2724-6329.21.04493-9)
 22. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, Jané-Salas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. *Oral Dis*. 2021;27 Suppl 3(Suppl 3):710-712. doi:[10.1111/odi.13382](https://doi.org/10.1111/odi.13382)
 23. Maheswari TN, Gnanasundaram N. Stress related oral diseases-A research study. *Int J Pharma Bio Sci*. 2010;1(3):1-10.
 24. Keyhan SO, Fallahi HR, Cheshmi B. Dysosmia and dysgeusia due to the 2019 Novel Coronavirus; a hypothesis that needs further investigation. *Maxillofac Plast Reconstr Surg*. 2020;42(1):9. doi:[10.1186/s40902-020-00254-7](https://doi.org/10.1186/s40902-020-00254-7)
 25. Levi M, van der Poll T. Inflammation and coagulation. *Crit Care Med*. 2010;38(2 Suppl):S26-S34. doi:[10.1097/CCM.0b013e3181c98d21](https://doi.org/10.1097/CCM.0b013e3181c98d21)
 26. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med*. 2021;27(5):892-903. doi:[10.1038/s41591-021-01296-8](https://doi.org/10.1038/s41591-021-01296-8)
 27. Ansari R, Gheitani M, Heidari F, Heidari F. Oral cavity lesions as a manifestation of the novel virus (COVID-19). *Oral Dis*. 2021;27 Suppl 3:771-772. doi:[10.1111/odi.13465](https://doi.org/10.1111/odi.13465)
 28. Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. *Theranostics*. 2020;10(16):7448-7464. doi:[10.7150/thno.48076](https://doi.org/10.7150/thno.48076)
 29. Wang C, Wu H, Ding X, et al. Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis?. *Med Hypotheses*. doi:[10.1016/j.mehy.2020.109789](https://doi.org/10.1016/j.mehy.2020.109789)
 30. De Vere R. Disorders of taste and smell. *Continuum (Minneapolis)*. 2017;23(2, Selected Topics in Outpatient Neurology):421-446. doi:[10.1212/CON.0000000000000463](https://doi.org/10.1212/CON.0000000000000463)
 31. Berenice Stella B. Variations in Olfactory Parameters in Different Olfactory Disorders: A Retrospective study. Dissertation. Christian Medical College; 2022.
 32. Matuck BF, Dolhnikoff M, Duarte-Neto AN, et al. Salivary glands are a target for SARS-CoV-2: a source for saliva contamination. *J Pathol*. 2021;254(3):239-243. doi:[10.1002/path.5679](https://doi.org/10.1002/path.5679)
 33. Iwabuchi H, Fujibayashi T, Yamane GY, Imai H, Nakao H. Relationship between hyposalivation and acute respiratory infection in dental outpatients. *Gerontology*. 2012;58(3):205-211. doi:[10.1159/000333147](https://doi.org/10.1159/000333147)
 34. Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, et al. Oral manifestations in patients with COVID-19: a living systematic review. *J Dent Res*. 2021;100(2):141-154. doi:[10.1177/0022034520957289](https://doi.org/10.1177/0022034520957289)
 35. Sampson V, Kamona N, Sampson A. Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?. *Br Dent J*. 2020;228(12):971-975. doi:[10.1038/s41415-020-1747-8](https://doi.org/10.1038/s41415-020-1747-8)

ACKNOWLEDGEMENTS

The authors thank the Ministry of Health for their cooperation and assistance in conducting the study.

CONFLICTS OF INTEREST

The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING

There was no source of funding for this research.

ETHICAL APPROVAL AND INFORMED CONSENT

Ethical approval was obtained from the Ethics Committee of the Directorate of Health Affairs, Ministry of Health, Jeddah, Saudi Arabia (Approval number: H-02-J-002; Date: 12 February 2020) and was registered at King Abdul-Aziz City for Science and Technology (IRB #1384). Patients provided informed consent.

DATA AVAILABILITY

The data supporting this research cannot be made available for privacy or other reasons.

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.